EUVIMEDEUVIMED entdecken
Crossref

Clinical Characteristics and Outcomes of Pediatric B‐Cell Acute Lymphoblastic Leukemia Harboring TP53 Mutations: A Single‐Center Retrospective Study

Jinlei Yin iD, Yuanyuan Zhang, Wei Lin, Ying Wu, Peijing Qi, Mingying Zhang, Zhigang Li iD, Ruidong Zhang iD

Pediatric Blood & Cancer · 2026-06 · 73 (6)

DOI: 10.1002/1545-5017.70276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 25.03.2026. Verfasst von Jinlei Yin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Hematologic Diseases, Hematology Center, Beijing Pediatric Research Institute, Beijing Children's Hospital, National Center for Childre…. Hauptthemen laut MEDLINE: Mutation, Tumor Suppressor Protein p53, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: Capital's Funds for Health Improvement and Research, Beijing Natural Science Foundation, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study analyzed the genetic mutation spectrum, clinical characteristics, and therapeutic outcomes of pediatric B‐cell acute lymphoblastic leukemia (B‐ALL) patients harboring TP53 mutations.

Methods

A retrospective analysis was conducted on 32 pediatric B‐ALL patients with TP53 mutations admitted to Beijing Children's Hospital, Capital Medical University, from November 2019 to August 2025. Clinical data, genetic characteristics, treatment responses, and prognostic outcomes were collected and analyzed.

Results

Among the 32 patients, the male‐to‐female ratio was 1.46:1 (19 males and 13 females). The median age at onset was 7.0 (range: 1.5–14.0) years. Fusion genes were detected in 47% (15/32) of patients, and abnormal karyotypes were present in 65% (20/31) of patients. The complete remission (CR) rate after induction therapy was 100%. At the end of follow‐up, 29 patients remained disease‐free, while 3 patients experienced relapse. Outcomes for relapsed patients were poor despite various salvage therapies, including novel agents, CAR‐T therapy, and HSCT, and treatments were complicated by severe chemotherapy‐related adverse events. No deaths occurred during the study period. The 3‐year event‐free survival (EFS) for the entire cohort was 92% ± 5%. Subgroup analyses based on mutation type and mutation site showed no significant differences in 3‐year EFS.

Conclusion

The incidence of TP53 mutations in pediatric B‐ALL is approximately 3%, and these cases are frequently accompanied by complex genetic features. Although the response to initial induction therapy is generally favorable, the prognosis becomes poor once relapse occurs, with limited efficacy observed from current salvage strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MutationTumor Suppressor Protein p53Precursor B-Cell Lymphoblastic Leukemia-LymphomaHumansMaleFemaleRetrospective StudiesChild, PreschoolChildInfantAdolescentPrognosisFollow-Up StudiesSurvival RateAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

Germline predispositionTP53 mutationVAFpediatric B‐ALLprognosis

Substanzen

Tumor Suppressor Protein p53TP53 protein, human

Autor:innen und Institutionen

  • Laboratory of Hematologic Diseases, Hematology Center, Beijing Pediatric Research Institute, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
  • Beijing Key Laboratory of Pediatric Hematology Oncology, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.
  • National Key Discipline of Pediatrics, Capital Medical University, Beijing, China.
  • Key Laboratory of Major Diseases in Children, Ministry of Education, Beijing, China.
  • Hematology Center, Beijing Children's Hospital, National Center for Children's Health, Capital Medical University, Beijing, China.

ORCID-Profile: Jinlei Yin, Zhigang Li, Ruidong Zhang

Förderung

  • Capital's Funds for Health Improvement and Research
  • Beijing Natural Science Foundation
  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Beijing Municipality

Zitieren

APA

Yin, J., Zhang, Y., Lin, W., Wu, Y., Qi, P., Zhang, M., Li, Z., & Zhang, R. (2026). Clinical Characteristics and Outcomes of Pediatric B‐Cell Acute Lymphoblastic Leukemia Harboring TP53 Mutations: A Single‐Center Retrospective Study. Pediatric Blood & Cancer, 73(6). https://doi.org/10.1002/1545-5017.70276

Vancouver

Yin J, Zhang Y, Lin W, Wu Y, Qi P, Zhang M, et al. Clinical Characteristics and Outcomes of Pediatric B‐Cell Acute Lymphoblastic Leukemia Harboring TP53 Mutations: A Single‐Center Retrospective Study. Pediatric Blood & Cancer. 2026;73(6). doi:10.1002/1545-5017.70276

BibTeX
@article{Yin2026,
  author = {Yin, Jinlei and Zhang, Yuanyuan and Lin, Wei and Wu, Ying and Qi, Peijing and Zhang, Mingying and Li, Zhigang and Zhang, Ruidong},
  title = {Clinical Characteristics and Outcomes of Pediatric B‐Cell Acute Lymphoblastic Leukemia Harboring TP53 Mutations: A Single‐Center Retrospective Study},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {6},
  doi = {10.1002/1545-5017.70276}
}
Kostenlos starten →